LHLindsay M. Henderson

Lindsay M. Henderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lindsay M. Henderson has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Katrina G. Claw

    Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Enrolled members of the Navajo Nation, Navajo Nation, USA

    2 shared publications
  • Kenneth E. Thummel

    Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington; Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington

    2 shared publications
  • Wylie Burke

    Department of Bioethics and Humanities, University of Washington, Seattle (W.B.).

    2 shared publications
  • Allan E. Rettie

    Departments of Pharmaceutics (L.M.H., K.E.T.), Biostatistics (T.A.T.), and Medicinal Chemistry (A.E.R.), University of Washington, Seattle, Washington; and Department of Obstetrics and Gynecology (S.E.H., B.B.B.), Oregon Health & Science University, Portland, Oregon

    1 shared publication
  • Bert B. Boyer

    Departments of Pharmaceutics (L.M.H., K.E.T.), Biostatistics (T.A.T.), and Medicinal Chemistry (A.E.R.), University of Washington, Seattle, Washington; and Department of Obstetrics and Gynecology (S.E.H., B.B.B.), Oregon Health & Science University, Portland, Oregon

    1 shared publication
  • Bert B. Boyer

    Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA

    1 shared publication

Latest Publications

  • Open Access

    A mechanistic PK/PD model to enable dose selection of the potent anti-tryptase antibody (MTPS9579A) in patients with moderate-to-severe asthma

    by Sharon M. Rymut, Lindsay M. Henderson, Victor Poon, Tracy L. Staton, Fang Cai, Siddharth Sukumaran, Horace Rhee, Ryan Owen, Saroja Ramanujan, Kenta Yoshida

    Tryptase, a protease implicated in asthma pathology, is secreted from mast cells upon activation during an inflammatory allergic response. MTPS9579A is a novel monoclonal antibody that inhibits tryptase activity by irreversibly dissociating the active tetramer into inactive monomers. This study assessed the relationship between MTPS9579A concentrations in healthy subjects and tryptase levels in serum and nasal mucosal lining fluid from healthy subjects and patients with moderate‐to‐severe asthma. These data were used to develop a mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model that quantitatively inter‐relates MTPS9579A exposure and inhibition of active tryptase in the airway of patients with asthma. From initial estimates of airway tryptase levels and drug partitioning, the PK/PD model predicted almost complete neutralization of active tryptase in the airway of patients with asthma with MTPS9579A doses of 900 mg and greater, administered intravenously (i.v.) once every 4 weeks (q4w). Suppression of active tryptase during an asthma exacerbation event was also evaluated using the model by simulating the administration of MTPS9579A during a 100‐fold increase in tryptase secretion in the local tissue. The PK/PD model predicted that 1800 mg MTPS9579A i.v. q4w results in 95.7% suppression of active tryptase at the steady‐state trough concentration. Understanding how the exposure‐response relationship of MTPS9579A in healthy subjects translates to patients with asthma is critical for future clinical studies assessing tryptase inhibition in the airway of patients with moderate‐to‐severe asthma.


  • Analysis of Drug-Drug Interaction Labeling Language and Clinical Recommendations for Newly Approved Drugs Evaluated With Digoxin, Midazolam, and S-Warfarin

    by Lindsay M. Henderson, Claire E. Steinbronn, Jingjing Yu, Catherine K. Yeung, Isabelle Ragueneau-Majlessi


  • Open Access

    In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup’ik Alaska Native Population

    by Lindsay M. Henderson, Scarlett E. Hopkins, Bert B. Boyer, Timothy A. Thornton, Allan E. Rettie, Kenneth E. Thummel

    Alaska Native people are under-represented in genetic research but have unique gene variation that may critically impact their response to pharmacotherapy. Full resequencing of CYP2C9 in a cross-section of this population identified CYP2C9 Met1Leu (M1L), a novel, relatively common single nucleotide polymorphism hypothesized to confer CYP2C9 poor metabolizer phenotype by disrupting the start codon. M1L is present at a minor allele frequency of 6.3% in Yup’ik Alaska Native people and thus can contribute to the risk of an adverse drug response from narrow-therapeutic-index CYP2C9 substrates such as (S)-warfarin. This study’s objective was to characterize the catalytic efficiency of the Leu1 variant enzyme in vivo by evaluating the pharmacokinetic behavior of naproxen, a probe substrate for CYP2C9 activity, in genotyped Yup’ik participants. We first confirmed the selectivity of (S)-naproxen O-demethylation by CYP2C9 using activity-phenotyped human liver microsomes and selective cytochrome P450 inhibitors and then developed and validated a novel liquid chromatography mass spectrometry method for simultaneous quantification of (S)-naproxen, (S)-O-desmethylnaproxen, and naproxen acyl glucuronide in human urine. The average ratio of (S)-O-desmethylnaproxen to unchanged (S)-naproxen in urine was 18.0 ± 8.0 (n = 11) for the homozygous CYP2C9Met1 reference group and 10.3 ± 6.6 (n = 11) for the Leu1 variant carrier group (P = 0.011). The effect of M1L variation on CYP2C9 function and its potential to alter the pharmacokinetics of drugs metabolized by the enzyme has clinical implications and should be included in a variant screening panel when pharmacogenetic testing in the Alaska Native population is warranted. Significance Statement The novel CYP2C9 Met1Leu variant in Alaska Native people was recently identified. This study validated (S)-naproxen as a CYP2C9 probe substrate to characterize the in vivo functional activity of the CYP2C9 Leu1 variant. The results of this pharmacogenetic-pharmacokinetic study suggest that the CYP2C9 Leu1 variant exhibits loss of enzyme activity. This finding may be important to consider when administering narrow-therapeutic-index medications metabolized by CYP2C9 and also compels further investigation to characterize novel genetic variation in understudied populations.


  • Open Access

    Pharmacogenomics in Indigenous Populations

    by Katrina G. Claw, Lindsay M. Henderson, Wylie Burke, Kenneth E. Thummel

    The integration of genomic technology into healthcare settings has the potential to transform health care through increased personalization of medical decisions. In particular, pharmacogenomic research on drug disposition and response can tailor and improve medication regimens for all patients by informing tests of function altering variation in drug metabolism and transport genes. Unfortunately, Indigenous peoples remain underrepresented in genomic and health research despite having a higher prevalence of heart disease, cancer, diabetes and stroke than any other population. Effective strategies to create research partnerships between tribal communities and genomic researchers are often lacking, yet such partnerships are needed for trustworthy research. As such, Indigenous populations are less likely to benefit from personalized medicine if they are not represented in studies that ascertain genotype‐phenotype relationships that can lead to improved drug treatment efficacy. We review what is currently known about pharmacogenetic variation in Indigenous populations and evaluate three case studies in which pharmacogenetic research with Indigenous populations were conducted. We highlight the importance of including Indigenous populations in future pharmacogenetic studies and discuss strategies for ethical engagement and collaboration in genomic research with Indigenous communities. The inclusion of Indigenous and other underrepresented communities in genomic research has the potential to expand our understanding of genomic influences on health and improve clinical approaches for all populations. Support or Funding Information NIGMS F32 GM119237 This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .


  • Open Access

    P450 Pharmacogenetics in Indigenous North American Populations

    by Lindsay M. Henderson, Katrina G. Claw, Erica L. Woodahl, Renee F. Robinson, Bert B. Boyer, Wylie Burke, Kenneth E. Thummel

    Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.